Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Blood Pressure Trajectories and Amyloid- and Tau-PET Burden in Cognitively Healthy Adults: The Framingham Heart Study
Aging, Dementia, Cognitive, and Behavioral Neurology
P1 - Poster Session 1 (8:00 AM-9:00 AM)
9-009

There is an increasing awareness of the role of BP variability in risk of clinical dementia. Prior studies have reported associations between greater lifetime SBP variability, greater DBP variability (at both mid- and late-life), and a steep decline in SBP (between mid- and late-life), and an increased risk of incident dementiaHowever, whether BP variation is associated with neuroimaging markers of preclinical dementia, namely amyloid and tau burden on brain PET, is less well explored.

To examine the relationship between blood pressure change and amyloid- and tau-PET abnormalities in cognitively healthy adults.

Dementia-free Framingham Heart Study Offspring (Gen 2) and 3rd generation (Gen 3) cohort participants with available data on remote (Gen 2, 2005-2008; Gen 3, 2002-2005) and recent (Gen 2, 2019-2022; Gen 3, 2016-2019) BP who participated in 11C-Pittsburgh Compound-B (PiB)-PET and/or 18F-Flortaucipir (FTP)-PET brain scans between 2016 to 2022. Multivariable linear regression was performed to examine the relationship between blood pressure and radiological changes.

The sample included 397 participants, including 41 Gen 2 participants (49% female, mean age 71+/- SD [standard deviation)) and 356 Gen 3 participants (51% female, mean age 55+/- SD 8). The median time between initial BP measurement and PET was 15 years. On multivariable linear regression analysis, a steep decline in DBP was associated with increased tau and amyloid deposition in the entorhinal cortex (p=0.04) but not any other brain regions. BP trajectories were not associated were amyloid deposition in any brain region.

In cognitively healthy adults, the development of hypertension in previously normotensive individuals and a steep decline in DBP over a median of 15 years were associated with preclinical entorhinal tau deposition, one of the earliest affected regions in Alzheimer’s disease. Maintenance of normotension in mid to late-life may reflect an important target for reducing the risk of preclinical tau deposition.

Authors/Disclosures
Martin D. Mulligan (University of Galway)
PRESENTER
Mr. Mulligan has nothing to disclose.
No disclosure on file
No disclosure on file
Keith A. Johnson, MD (MGH) Dr. Johnson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Johnson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. An immediate family member of Dr. Johnson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AC Immune. An immediate family member of Dr. Johnson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shionogi. An immediate family member of Dr. Johnson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Prothena. An immediate family member of Dr. Johnson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NervGen. An immediate family member of Dr. Johnson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Oligomerix. Dr. Johnson has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AC Immune. The institution of Dr. Johnson has received research support from National Institute on Aging. The institution of an immediate family member of Dr. Johnson has received research support from Alzheimer's Association. The institution of an immediate family member of Dr. Johnson has received research support from Eli Lilly and Co. The institution of Dr. Johnson has received research support from Eisai. The institution of an immediate family member of Dr. Johnson has received research support from Eisai.
No disclosure on file
Sudha Seshadri, MD, FAAN (Glenn Biggs Institute for Alzheimer'S and Neurodegenerative Diseases) Dr. Seshadri has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Seshadri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. The institution of Dr. Seshadri has received research support from NIH. The institution of Dr. Seshadri has received research support from Alzheimer Association.
Emer McGrath, MBChB (HRB Clinical Research Facility, University of Galway) Dr. McGrath has nothing to disclose.